Neonatal dexamethasone treatment exacerbates hypoxic-ischemic brain injury

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Chang, Kan Hsun ^a   Yeh, Che Ming ^b   Yeh, Chia Yu ^a   Huang, Chiung Chun ^a   Hsu, Kuei Sen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; FRONTAL CORTEX; GENE EXPRESSION; GLIOMA CELL; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MALE; MOLECULAR MECHANICS; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANIMALS, NEWBORN; BRAIN INJURIES; CEFTRIAXONE; CELL LINE, TUMOR; CEREBRAL CORTEX; DEXAMETHASONE; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATES; HYPOXIA-ISCHEMIA, BRAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER;

RATTUS;

EID: 84876173224     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-18     Document Type: Article

References (39)

1. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, Chien LY, Sale J, Pediatrics 2000 106 5 1070 1079 10.1542/peds.106.5.1070 11061777
2. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, Verter J, Temprosa M, Wright LL, Ehrenkranz RA, Fanaroff AA, Stark A, Carlo W, Tyson JE, Donovan EF, Shankaran S, Stevenson DK, Pediatrics 2001 107 1 1 10.1542/peds.107.1.e1 11134465
3. Glucocorticoids, prenatal stress and the programming of disease. Harris A, Seckl J, Horm Behav 2011 59 3 279 289 10.1016/j.yhbeh.2010.06.007 20591431
4. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, Dillard RG, Pediatrics 1999 104 1 15 21 10.1542/peds.104.1.15 10390254 (Pubitemid 29315841)
5. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, Yurman S, Dolfin T, Kogan A, Dollberg S, Arbel E, Goldberg M, Gur I, Naor N, Sirota L, Mogilner S, Zaritsky A, Barak M, Gottfried E, Arch Dis Child Fetal Neonatal Ed 2000 83 3 177 F181 10.1136/fn.83.3.F177 11040164
6. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. Barrington KJ, BMC Pediatr 2001 1 1 10.1186/1471-2431-1-1 11248841 (Pubitemid 38729198)
7. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH, N Engl J Med 2004 350 13 1304 1313 10.1056/NEJMoa032089 15044641 (Pubitemid 38375365)
8. Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity: involvement of the NMDA receptor complex. Kamphuis PJ, Gardoni F, Kamal A, Croiset G, Bakker JM, Cattabeni F, Gispen WH, Van Bel F, Di Luca M, Wiegant VM, FASEB J 2003 17 8 911 913 12626441
9. Effects of neonatal dexamethasone treatment on hippocampal synaptic function. Lin HJ, Huang CC, Hsu KS, Ann Neurol 2006 59 6 939 951 10.1002/ana.20885 16718693 (Pubitemid 43830926)
10. The role of growth retardation in lasting effects of neonatal dexamethasone treatment on hippocampal synaptic function. Wang YC, Huang CC, Hsu KS, PLoS One 2010 5 9 12806 10.1371/journal.pone.0012806 20877626
11. Hypoxic-ischemic encephalopathy. Vannucci RC, Am J Perinatol 2000 17 3 113 120 10.1055/s-2000-9293 11012134
12. MK-801 protects the neonatal brain from hypoxic-ischemic damage. McDonald JW, Silverstein FS, Johnston MV, Eur J Pharmacol 1987 140 3 359 361 10.1016/0014-2999(87)90295-0 2820765 (Pubitemid 17145361)
13. Molecular and biochemical mechanisms of perinatal brain injury. Vexler ZS, Ferriero DM, Semin Neonatol 2001 6 2 99 108 10.1053/siny.2001.0041 11483016 (Pubitemid 32705981)
14. Effects of short-term dexamethasone treatment during pregnancy on the development of the immune system and the hypothalamo-pituitary adrenal axis in the rat. Bakker JM, Schmidt ED, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ, Van Rees EP, J Neuroimmunol 1995 63 2 183 191 10.1016/0165-5728(95)00152-2 8550816 (Pubitemid 26019012)
15. Dexamethasone pre-treatment protects brain against hypoxic-ischemic injury partially through up-regulation of vascular endothelial growth factor A in neonatal rats. Feng Y, Rhodes PG, Bhatt AJ, Neuroscience 2011 179 223 232 21277350
16. Glucocorticoid prevention of neonatal hypoxic-ischemic damage: role of hyperglycemia and antioxidant enzymes. Tuor UI, Simone CS, Arellano R, Tanswell K, Post M, Brain Res 1993 604 1-2 165 172 8457844 (Pubitemid 23080110)
17. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. Cummings JJ, D'Eugenio DB, Gross SJ, N Engl J Med 1989 320 23 1505 1510 10.1056/NEJM198906083202301 2657423 (Pubitemid 19145801)
18. Comparative aspects of the brain growth spurt. Dobbing J, Sands J, Early Hum Dev 1979 39 1 79 83 (Pubitemid 9141710)
19. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, Holtzman DM, J Clin Invest 1998 101 9 1992 1999 10.1172/JCI2169 9576764 (Pubitemid 28226119)
20. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Camacho A, Massieu L, Arch Med Res 2006 37 1 11 18 10.1016/j.arcmed.2005.05.014 16314180 (Pubitemid 41727885)
21. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Anderson CM, Swanson RA, Glia 2000 32 1 1 14 10.1002/1098-1136(200010)32:1<1::AID-GLIA10>3.0.CO;2-W 10975906
22. Ceftriaxone attenuates hypoxic-ischemic brain injury in neonatal rats. Lai PC, Huang YT, Wu CC, Lai CJ, Wang PJ, Chiu TH, J Biomed Sci 2011 18 69 10.1186/1423-0127-18-69 21933448
23. Perinatal hypoxia-ischemia disrupts striatal high-affinity [§ssup§3§esup§H]glutamate uptake into synaptosomes. Silverstein FS, Buchanan K, Johnston MV, J Neurochem 1986 47 5 1614 1619 10.1111/j.1471-4159.1986.tb00803.x 2876058 (Pubitemid 17174684)
24. NF-κB contributes to neuron-dependent induction of glutamate transporter-1 expression in astrocytes. Ghosh M, Yang Y, Rothstein JD, Robinson MB, J Neurosci 2011 31 50 9159 9169 21697367
25. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB, J Biol Chem 2008 283 19 13116 13123 10.1074/jbc.M707697200 18326497
26. β-amyloid and brain-derived neurotrophic factor, BDNF, up-regulate the expression of glutamate transporter GLT-1/EAAT2 via different signaling pathways utilizing transcription factor NF-κB. Rodriguez-Kern A, Gegelashvili M, Schousboe A, Zhang J, Sung L, Gegelashvili G, Neurochem Int 2003 43 4-5 363 370 12742080 (Pubitemid 36561289)
27. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M, Science 1995 270 5234 286 290 10.1126/science.270.5234.286 7569976
28. Role of transcriptional activation of IκB-α in mediation of immunosuppression by glucocorticoids. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr, Science 1995 270 5234 283 286 10.1126/science.270.5234.283 7569975
29. IκB-α -independent downregulation of NF-κB activity by glucocorticoid receptor. Heck S, Bender K, Kullmann M, Göttlicher M, Herrlich P, Cato AC, EMBO J 1997 16 15 4698 4707 10.1093/emboj/16.15.4698 9303314 (Pubitemid 27326607)
30. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Ray A, Prefontaine KE, Proc Natl Acad Sci USA 1994 91 2 752 756 10.1073/pnas.91.2.752 8290595 (Pubitemid 24041480)
31. Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. Zschocke J, Bayatti N, Clement AM, Witan H, Figiel M, Engele J, Behl C, J Biol Chem 2005 280 41 34924 34932 10.1074/jbc.M502581200 16079146 (Pubitemid 41504627)
32. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB, Nature 2005 433 7021 73 77 10.1038/nature03180 15635412 (Pubitemid 40101145)
33. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB, J Cell Physiol 2011 226 10 2484 2493 10.1002/jcp.22609 21792905
34. Dexamethasone prevents hypoxic-ischemic brain damage in the neonatal rat. Barks JD, Post M, Tuor UI, Pediatr Res 1991 29 6 558 563 10.1203/00006450- 199106010-00008 1866211
35. Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: mechanisms and possible interventions. Li Y, Gonzalez P, Zhang L, Prog Neurobiol 2012 98 2 145 165 10.1016/j.pneurobio.2012.05.010 22627492
36. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Amberger VR, Hensel T, Ogata N, Schwab ME, Cancer Res 1998 58 1 149 158 9426071 (Pubitemid 28027730)
37. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Saal D, Dong Y, Bonci A, Malenka RC, Neuron 2003 37 4 577 582 10.1016/S0896-6273(03)00021-7 12597856 (Pubitemid 36262980)
38. Glial plasmalemmal vesicles: a subcellular fraction from rat hippocampal homogenate distinct from synaptosomes. Nakamura Y, Iga K, Shibata T, Shudo M, Kataoka K, Glia 1993 9 1 48 56 10.1002/glia.440090107 7902337
39. Acute stress impairs hippocampal mossy fiber-CA3 long-term potentiation by enhancing cAMP-specific phosphodiesterase 4 activity. Chen CC, Yang CH, Huang CC, Hsu KS, Neuropsychopharmacol 2010 35 7 1605 1617 10.1038/npp.2010.33